Rubicon Research Share Price in Focus as Its Subsidiary Enters Agreement with Gen1E Lifesciences Inc

Rubicon Research Limited has informed the stock exchanges that its wholly owned subsidiary, Advagen Holdings Inc., has entered into a definitive agreement with Gen1E Lifesciences Inc. The company made this disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Details of the Agreement

Under the agreement, Advagen will acquire Series Prime Preferred Stock of Gen1E Lifesciences for a total amount of up to $3 million. The investment will be made in tranches. A cash investment of $2 million will be completed in 2 phases by March 31, 2026. 

The remaining $1 million will be linked to development activities carried out by Rubicon or its subsidiary until December 31, 2027, based on a milestone-based share issuance model.

Nature of Investment

The transaction is a minority investment and will not result in control or a change in management. Once all milestones are met, Advagen’s investment will be convertible into about 2.2% of Gen1E’s common stock. The deal does not fall under related party transactions, and neither Rubicon nor its promoter group has any existing interest in Gen1E Lifesciences.

About Gen1E Lifesciences

Gen1E Lifesciences Inc. is a pharmaceutical company based in Palo Alto, California, with a laboratory in Mountain View, California. The company was incorporated on May 23, 2018, and is currently at a pre-revenue stage, with no reported turnover in the last three financial years. Its business focuses on the development of pharmaceutical product candidates.

Rubicon Research Share Price Performance

As of October 23, 2025, 10:07 AM, Rubicon Research share price was trading at ₹607.10, a 0.78% decline from the previous closing price.

Read More: Sikko Industries Board Approves Stock Split and 1:1 Bonus Issue!

Conclusion

The acquisition process is expected to be completed within the mentioned timelines, subject to milestone progress and completion of all formalities as per the agreement.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions. 

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.